Cardiac amyloidosis: where are we today?

Area of Science:

• Cardiology
• Oncology
• Genetics

Background:

• Cardiac amyloidosis, though considered rare, frequently affects the heart and is a key prognostic factor.
• Monoclonal immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis are the primary types, with distinct age of onset and risk factors.
• ATTR amyloidosis, particularly the senile form, may be underdiagnosed, with a notable genetic predisposition in individuals of African descent.

Purpose of the Study:

• To review recent advancements in the diagnosis and management of cardiac amyloidosis.
• To highlight the growing importance of accurate diagnosis due to emerging therapies.
• To discuss the different types of cardiac amyloidosis and their specific characteristics.

Main Methods:

• Review of recent diagnostic imaging techniques for enhanced accuracy.
• Analysis of serum cardiac biomarkers for staging AL amyloidosis severity and treatment response.
• Examination of genetic factors contributing to ATTR amyloidosis susceptibility.

Main Results:

• New diagnostic tools improve accuracy in identifying cardiac amyloidosis.
• Serum biomarkers are crucial for managing AL amyloidosis.
• A TTR gene variant increases susceptibility to cardiac ATTR amyloidosis in specific populations.

Conclusions:

• Cardiac amyloidosis diagnosis and management are rapidly evolving.
• Emerging therapies offer new hope for patients with AL and ATTR amyloidosis.
• Understanding the prevalence and genetic basis of cardiac amyloidosis is critical for future treatment strategies.